Board strengthened ahead of completion and market launch of disruptive cancer diagnostic platform
- Veteran Roche executive with more than 35 years of industry experience
- Pioneer in the early adoption of polymerase chain reaction (PCR) technology
- Appointment follows completion of $12 million Series A financing
Cambridge, UK 10 September 2020 – Biofidelity Ltd, the cancer diagnostics company, today announces the appointment of Dr. Heiner Dreismann, former President and CEO of Roche Molecular Systems, as Chairman with immediate effect. Biofidelity recently announced the successful completion of a $12m Series A financing led by BlueYard Capital and backed by experienced investors including Longwall Ventures and Agilent Technologies.
Dr Barnaby Balmforth, Chief Executive Officer of Biofidelity, commented: “We are delighted to welcome Heiner to the helm of the Company as Chairman. Heiner’s diagnostics and industry expertise will be invaluable as we seek to revolutionize access to best-in-class cancer diagnostics. Biofidelity’s unique technology platform provides high quality, comprehensive and clinically actionable information of guideline-recommended markers in a simple, high precision, rapid diagnostic to ensure every patient has access to the right treatment at the right time.”
Dr. Heiner Dreismann, added: “I’m delighted to be joining the Biofidelity Board as Chairman, a decision which has been driven by the vast opportunity for the Biofidelity technology. I believe its novel diagnostic platform has the potential to change the dynamics of cancer diagnosis and treatment. With the recent completion of a Series A financing led by high quality investors, Biofidelity’s vision of providing better screening and monitoring tools to ensure all cancer patients receive the most appropriate therapies has moved significantly closer to being delivered. I look forward to working with Barney and his excellent team.”
Dr. Dreismann joins Biofidelity with more than 35 years of experience in the leadership of high growth life science and healthcare businesses. He has held numerous national and international management positions including as Head of Global Business Development, Roche Diagnostics, and as a Member of Roche’s Global Diagnostic Executive Committee. From 2000 to 2006 he was President and CEO of Roche Molecular Systems in Pleasanton, California.
Dr. Dreismann currently serves on the boards of several public and private life sciences and health care companies in the United States, Europe and Israel.
Biofidelity, a private company founded in 2019 in Cambridge, UK, is revolutionising access to best-in-class cancer diagnostics, breaking down the barriers to better screening, monitoring and treatment for all cancer patients.
Its disruptive diagnostic technology platform will provide oncologists with clinically actionable data based on ultra-sensitive detection of markers recommended in cancer treatment guidelines, enabling them to prescribe the right cancer drug at the right time. It is designed to combine fast and easy-to-interpret results with affordability and straightforward adoption on existing laboratory infrastructure, enabling many more laboratories to offer high quality cancer diagnostics.
Biofidelity is initially focusing on diagnosis of non-small cell lung and colorectal cancer, with potential in a broad range of cancers and further applications in the detection of resistance to therapy and disease recurrence.